Inmunology INMB 2024 Investor Presentation XPro INKmune

Inmunology presents its XPro and INKmune immunology platforms designed to repair innate immune dysfunction across multiple indications. The June 2024 presentation outlines clinical milestones including Phase 2 trials in atopic dermatitis, treatment-resistant depression, and metastatic castration-resistant prostate cancer, with key data readouts expected through 2025.